Unlocking miRNA Therapeutics: Protecting Liver Grafts and Suppressing HCC Recurrence

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a major global health burden.1 Liver transplantation (LT) remains the most effective treatment for selected patients, addressing both malignancy and underlying liver disease.2 However, posttransplant recurrence remains a significant challenge, influenced by tumor biology and perioperative factors, including ischemia/reperfusion injury (IRI). Hepatic IRI, an unavoidable consequence of LT, exacerbates inflammation and oxidative stress, creating a microenvironment conducive to tumor progression.3,4 Understanding the molecular mechanisms linking IRI and HCC recurrence is crucial for developing targeted strategies to improve post-LT outcomes. MicroRNAs (miRNAs) have emerged as key posttranscriptional regulators of gene expression, affecting inflammation, apoptosis, and tumor progression. Dysregulated miRNA expression is implicated in both HCC development and IRI pathogenesis.5 Among these, miR-374b-5p has been linked to liver disease, but its role in the interaction between IRI and HCC recurrence remains unclear. Additionally, clinical application of miRNA-based therapies has been hindered by challenges in targeted delivery. The study by Xie et al6 presented a novel liver-targeted, esterase-responsive gene delivery system, G-LERP/miR-374i-b, designed to encapsulate an antagomir of miR-374b-5p to mitigate both IRI and HCC recurrence. The authors demonstrate that high miR-374b-5p expression is associated with poor prognosis in patients with HCC, correlating with larger tumor size, microvascular invasion, and worse survival. Using a galactose-modified lipid nanoparticle, they achieved liver-specific accumulation of G-LERP/miR-374i-b, effectively downregulating miR-374b-5p in hepatocytes. This approach reduced IRI by lowering oxidative stress and inflammatory cytokines, such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, while increasing anti-inflammatory IL-10. Liver function markers (alanine transaminase and aspartate transaminase) were significantly reduced, indicating hepatocyte protection. Furthermore, in an orthotopic HCC recurrence model, miR-374b-5p inhibition decreased tumor growth, as confirmed by reduced Ki67 staining and increased apoptosis (terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay). Additionally, immune profiling revealed increased cytotoxic T-lymphocyte infiltration and reduced neutrophils and inflammatory macrophages, suggesting an improved tumor microenvironment. The liver-targeted nano-delivery system also demonstrated sustained gene silencing while minimizing systemic toxicity. If validated in larger studies and more clinically relevant models, these findings could have significant implications for reducing graft injury, early allograft dysfunction, and graft failure post-LT. This therapy may help minimize transplant-related liver injury, shorten hospital stays, and improve graft survival. Furthermore, reducing inflammation and enhancing hepatocyte resistance may improve the viability of marginal grafts currently deemed unsuitable for transplantation, thereby expanding the donor pool. Given the need for effective strategies to prevent HCC recurrence after LT, this approach could play a critical role in improving long-term outcomes. Despite its promising findings, the study has limitations that warrant further investigation. The use of a murine Hepa1-6 orthotopic tumor model does not fully replicate human HCC complexity, as it lacks key tumor-stroma interactions and immune modulation found in patient-derived xenografts or humanized mouse models. Additionally, although the study achieved liver-targeted delivery, potential off-target effects in other organs were not assessed. Given that miRNAs regulate multiple pathways, systemic inhibition of miR-374b-5p could have unintended effects beyond the liver.7 Moreover, long-term outcomes, such as fibrosis, immune modulation, and chronic toxicity, were not evaluated. Although the study demonstrates short-term hepatoprotection, further research is needed to assess its impact on long-term graft survival and recurrence-free outcomes in clinically relevant settings. This study adds to the growing evidence supporting miRNA-based therapies as potential tools in transplantation and oncology.8-10 By demonstrating that miR-374b-5p inhibition mitigates IRI and suppresses tumor progression, the authors provide a compelling rationale for further exploration of RNA-targeted therapies in liver disease. However, before clinical application, validation in large animal models and clinical trials is necessary to determine long-term safety, efficacy, and interactions with standard immunosuppressive regimens.